Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2010. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding an increase in their ordinary share interests.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details rather than financial performance metrics.
Material Changes
There are no material changes to financial performance reported in this filing. The document details a specific transaction where directors and connected persons increased their shareholdings through the re-investment of dividends paid on April 8, 2010.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Transaction Date: April 15, 2010.
- Share Price: Shares were purchased at a price of £12.79 per share.
- Transaction Type: Increase in interests via dividend re-investment.
- Key Participants: Notable increases were recorded for Mr. J R Stéphenne (572.40 shares), Mr. J M Clarke (182.97 shares), and Dr. M M Slaoui (174.15 shares).
- Notification Date: The company was advised of these transactions on April 16, 2010.